Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The journey to effectively treat Hepatitis C Virus (HCV) infection has been a remarkable one, marked by significant scientific milestones. Historically, treatment options were limited, arduous, and often ineffective. The introduction of sofosbuvir, however, represents a pivotal moment, fundamentally altering the therapeutic landscape and offering a cure to millions. NINGBO INNO PHARMCHEM CO.,LTD. is proud to contribute to the supply of APIs that have driven such monumental shifts in healthcare.
For decades, the primary treatment for chronic HCV infection involved therapies centered around interferon. These regimens were lengthy, typically lasting 6 to 12 months, and were notorious for their debilitating side effects. Patients often experienced fatigue, depression, anemia, and flu-like symptoms, leading to poor adherence and low cure rates, particularly for the most common genotype in many regions, genotype 1. The limited efficacy and severe tolerability issues meant that many patients either did not complete treatment or did not achieve a cure.
The development of direct-acting antivirals (DAAs) marked the beginning of a new era. Sofosbuvir, a groundbreaking nucleotide analog inhibitor of the NS5B polymerase, emerged as a key component in these new regimens. Its highly potent mechanism of action provided significantly higher cure rates compared to previous treatments. Crucially, sofosbuvir enabled the development of interferon-free treatment regimens. These regimens, often combining sofosbuvir with other DAAs like ledipasvir or velpatasvir, offered a cure with dramatically improved tolerability and much shorter treatment durations, typically 12 weeks.
The significance of the Sofosbuvir development history cannot be overstated. It moved HCV treatment from a challenging, often ineffective, and poorly tolerated endeavor to a highly effective, well-tolerated, and curative one for the vast majority of patients. The understanding of Sofosbuvir mechanism of action and its combination with other antivirals laid the foundation for pangenotypic therapies that cover all major HCV genotypes, simplifying treatment protocols and expanding access to cure.
NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role in this progression by ensuring the consistent supply of high-quality sofosbuvir. As we reflect on the evolution of HCV treatment, the story of sofosbuvir is a powerful testament to the impact of pharmaceutical innovation on global health, transforming patient outcomes and offering renewed hope.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
